Jnk3
o/o mice were not affected by KA. Pharmacological blockage of JNK3 activity impaired PrP C -dependent neurotoxicity. Furthermore, our results indicate that JNK3 activation depends on the interaction of PrP C with postsynaptic density 95 protein (PSD-95) and glutamate receptor 6/7 (GluR6/7). Indeed, GluR6-PSD-95 interaction after KA injections was favored by the absence of PrP C . Finally, neurotoxicity in Prnp knockout mice was reversed by an AMPA/KA inhibitor (6,7-dinitroquinoxaline-2,3-dione) and the GluR6 antagonist NS-102. We conclude that the protection afforded by PrP C against KA is due to its ability to modulate GluR6/7-mediated neurotransmission and hence JNK3 activation.
INTRODUCTION
The abnormal processing of cellular prion protein (PrP C ) gives rise to PrP SC , or pathogenic prion, which is the etiologic agent of several transmissible spongiform encephalopathies (reviewed in Aguzzi et al., 2007; Aguzzi and Calella, 2009; Linden et al., 2008) . These devastating encephalopathies are characterized by severe histological changes, including extensive neuronal death, reactive gliosis, and neuroinflammation, concomitant to the accumulation of the aggregated misfolded form of PrP C in affected brains. Although necessary for prion propagation and infectivity (Weissmann et al., 1994) , the repertoire of physiological roles of PrP C remains to be fully determined. Indeed, PrP C has been implicated in a wide range of neural functions, such as copper homeostasis (Brown et al., 1997 (Brown et al., , 1998 Vassallo and Herms, 2003) , neurotransmission (Maglio et al., 2004 ; Prestori et al., 2008; Rangel et al., 2009) , stem-cell proliferation and differentiation (Steele et al., 2006) , malignant glioma proliferation (Erlich et al., 2007) , neurite outgrowth (Chen et al., 2003; Santuccione et al., 2005) , and, more recently, putative cross-talk between neurodegenerative diseases (Lauren et al., 2009; Gavin et al., 2010; Gunther and Strittmatter, 2010) .
Monitoring Editor
Early in vitro studies with prion protein gene Prnp o/o mice (Zürich I) (Bueler et al., 1992) showed that cultured Prnp o/o neurons were more prone to die than Prnp +/+ neurons after serum withdrawal or other treatments (Kuwahara et al., 1999) . Subsequent studies (Brown et al., 2002; Rambold et al., 2008; Aude-Garcia et al., 2011) indicated that PrP C might play a neuroprotective function in the context of excitotoxic lesions. Indeed, it was demonstrated in rats that Prnp is overexpressed in ischemic brains and protects cortical neurons after ischemia (McLennan et al., 2004; Shyu et al., 2005; Spudich et al., 2005; Weise et al., 2006; Mitteregger et al., 2007) . In fact, cells overexpressing PrP C show increased toxicity after endoplasmic reticulum stress (Anantharam et al., 2008) . Neuroprotective effects of PrP C after central nervous system insults have been associated with both extracellular and intracellular effectors (e.g., the stress-inducedphosphoprotein 1) and are mediated by PI3K-mTOR signaling (Martins et al., 2010; Roffe et al., 2010) . However, although it is involved in Alzheimer's disease (Lauren et al., 2009 ), PrP C does not act as a major modulator in a panel of neurodegenerative disease models (Steele et al., 2009) .
In neurons, PrP C has been localized in axons at the synapse (Fournier et al., 2000; Fournier, 2008) , which might be consistent with reports of deficits in neurotransmission in Prnp knockout mice (Maglio et al., 2004 (Maglio et al., , 2006 Khosravani et al., 2008; Prestori et al., 2008; Rangel et al., 2009) . Indeed, PrP C knockout mice are more prone to cell death after kainate (KA) injections than are Prnp +/+ animals (Walz et al., 1999; Rangel et al., 2007 Rangel et al., , 2009 ). In addition, Prnp o/o neurons are also highly susceptible to acute N-methyl-d-aspartic acid (NMDA) or KA treatment in hippocampal slices (Rangel et al., 2007; Khosravani et al., 2008) . These findings suggest that PrP C can modulate signaling cascades by activating stress-protective pathways, or by inhibiting cytotoxic pathways (reviewed in Westergard et al., 2007; Nicolas et al., 2009) . Although the exact mechanism(s) are unknown, the neuroprotective function may be associated with differential expression of glutamate receptor subunits or the modulation of ligand/receptor affinities (Maglio et al., 2004; Khosravani et al., 2008; Rangel et al., 2009) . In particular, it remains to be established whether PrP C alters KA receptor-mediated neurotransmission at the neuron membrane. In fact, PrP C -binding proteins include, among others, membrane receptors (Rutishauser et al., 2009) , and two recent studies reported cell-specific effects of glutamate and the role of PrP C in these processes. Indeed, group I metabotropic glutamate receptors are involved in the transduction of cellular signals triggered by PrP C , which modulates neurite outgrowth (Beraldo et al., 2011) . In addition, in NMDA-mediated toxicity, the protective role of PrP C is mediated by the silencing of NMDA receptors containing N-methyl-d-aspartate receptor subtype 2 (NR2D) subunits (Khosravani et al., 2008) .
In a previous study, we reported the increased presence of phosphorylated c-Jun N-terminal kinase 3 (JNK) in dying pyramidal neurons in the CA1 of the hippocampus of Prnp knockout mice after KA treatment (Rangel et al., 2007) . Here we show that KA-induced excitotoxicity in Prnp knockout mice depends on JNK3 activity, by developing a double-knockout mouse lacking PrP C and JNK3 expression and analyzing it by using gene expression and pharmacological approaches. Furthermore, we propose a mechanism by which PrP C regulates the KA receptor function through interaction, at the postsynaptic level, with the glutamate receptor 6/7 (GluR6/7) and the postsynaptic density 95 protein (PSD-95), which in turn modulates JNK3 activity. 
RESULTS

Enhanced
Jnk3
+/+ animals developed profound hypoactivity and immobility (grades I-II). After successive injections, hyperactivity (grade III) and scratching (grade IV) were often observed. Some mice progressed to a loss of balance control (grade V) and further chronic whole-body convulsions (grade VI). The bouncing activity commonly referred to as ''popcorn'' behavior was included in grade VI. After the behavioral study, mice were numbered and kept in separate boxes until histological or biochemical studies; see later discussion. Twelve hours after KA treatment, Prnp (Walz et al., 1999; Rangel et al., 2007 Rangel et al., , 2009 
+/o mice were not affected by KA treatment as described (Yang et al., 1997) . 
Decreased seizures in
Jnk3
+/+ mice, and neither of these proteins was detected in the double-knockout mice, as expected ( Figure 1A ). Next we analyzed in more detail the time course of the seizure score after KA injection ( Figure 1B 
o/o mice 24 h after KA treatment by using Fluoro-Jade B staining (Schmued and Hopkins, 2000;  Figure 1C ). Numerous Fluoro-Jade B-positive pyramidal neurons were observed in the CA1 and CA3 regions of 
+/+ hippocampus. In the other genotypes Fluoro-Jade B labeling was rare and generally pale ( Figure 1C ). To further corroborate the death of these neurons, we applied in parallel sections the in situ nick-translation technique with biotinylated-UTP to determine the DNA fragmentation level (TUNEL technique, by using ApopTag kit; Heatwole, 1999;  Figure 1D 
+/+ mice with any of the other two genotypes. 
+/+ primary cortical neurons were infected with a lentivirus carrying a small interfering RNA (siRNA) interference sequence for Prnp. Cells infected with lentivirus showed an 81% decrease in PrP C expression ( Figure 2A ). After exposure to KA, cells infected with lentivirus showed a statistically significant 29% decrease in survival ( Figure 2B ) compared with parallel enhanced green fluorescent protein (eGFP)-infected cultures ( Figure 2B ). Thus, although similar data were previously described in neuroblastoma cells (N 2 A) using interference RNA against Prnp (Rangel et al., 2007) , this is the first observation of KA-mediated cell death after acute PrP C down-regulation in Prnp
+/+ neurons. This finding reinforces the notion that decreased expression of PrP C compromises neuronal viability after acute KA treatment. 
+/+ mice ( Figure 3A ). These data corroborate the reported data of 
o/o mice after 24 h of KA treatment. Results are obtained from nine mice per genotype. DG, dentate gyrus; CA1-3, hippocampal regions 1 and 3; gl, granule cell layer; h, hilus; ml, molecular layer; sl, stratum lucidum; slm, stratum lacunosummoleculare; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bar, C, top, 200 μm; C, bottom, 100 μm; D, 100 μm. Asterisks in E indicate statistical significance (***p < 0.001, ANOVA test).
C neuroprotection | 3045 ERK1/2 activation in Prnp knockout mice (Brown et al., 2002) . In parallel to the phosphorylation of ERK1/2 in all genotypes after KA treatment, an increase in p-JNK3 and p-c-Jun Ser 63 was observed in Figure 3A ). Finally, p53, which was recently reported to be activated in a JNKdependent manner in dying hippocampal neurons after glutamate and/or KA (Choi et al., 2011) , was phosphorylated at Ser-15 and activated in Prnp
+/+ hippocampus after KA treatment. These results suggest that signaling pathways other than the JNK3 pathway are activated after KA treatment. Indeed, we determined the cellular expression of ERK1/2 in detail in treated mice ( Figure 3 , B and C). p-ERK1/2 staining was strong in hippocampal mossy fibers at the stratum lucidum in , after 24 h of KA treatment. Double-labeling techniques with glial fibrillary acidic protein (GFAP) and p-ERK1/2 revealed a second group on p-ERK1/2-stained cells at CA1 and CA3 regions ( Figure 3C) The JNK3 pathway is implicated in c-fos and c-jun activation after glutamate treatment (Brami-Cherrier et al., 2007) . To discriminate the particular contribution of JNK3 to c-jun and c-fos expression in our experiments, we performed quantitative real-time PCR (RT-qPCR; Figure 4 ). Data obtained demonstrate that both c-jun and c-fos were overexpressed in the hippocampus of Prnp
+/+ mice 6 h after KA administration (4.10-and 49.2-fold increase, respectively; Figure 4A) 
+/+ levels. These results support the idea that other KA-activated pathways are the main contributors to the overexpression of both early genes. To examine this hypothesis, we analyzed the differential expression of cyclooxygenase-2 (cox-2), a molecular target of JNK activation in neurodegeneration and inflammation activated by activator protein-1 (AP-1; Hunot et al., 2004 
+/+ neurons is associated with intrinsic synaptic properties.
Coimmunoprecipitation of PrP
C with PSD-95 and GluR6/7 in the PSD fractions
To investigate the participation of PrP C in the neurotoxic effects of KA, we examined whether PrP C exerts its neuroprotective function by modulating the intracellular signaling triggered by KA receptor after ligand binding. Because neuronal depolarization mediated by KA requires the interaction of the GluR6/7 subunit of KA receptor with PSD-95 and MLK3 to form a trimeric complex (Pei et al., 2006; Li et al., 2010) Figure 6A ). Correct purification of the PSD fractions was corroborated since the percentage of PSD-95 in this fraction was 91.6% of total PSD-95. Results revealed no changes in subcellular distribution of these proteins among genotypes. As expected, PrP C was detected in all cell compartments but enriched in PSD fractions, where GluR6/7 and PSD-95 were also found.
These results suggested a putative interaction between GluR6/7 and PrP C . To explore this possibility, we performed coimmunoprecipitation experiments from whole Prnp +/+ Jnk3 +/+ hippocampus protein extracts and PSD fractions using two different PrP C antibodies (6H4 and SAF61; see Materials and Methods; Figure 6B ). Results indicated that PrP C interacts with PSD-95 and GluR6/7 both in whole-hippocampus extracts and in purified PSD. As expected, both interactions were stronger in the PSD fraction ( Figure 6B ). Taken together, these results implicate PrP C in the binding of PSD-95 with the KA receptor containing GluR6/7. This would allow the formation of the ternary complex (GluR6/7-PSD-95-MLK3), which in turn activates the JNK3 pathway. Thus, to determine this, we immunoprecipitated PSD-95 in hippocampal protein extracts from Prnp +/+ Jnk3 +/+ and Prnp o/o Jnk3 +/+ mice to measure the amount of GluR6/7 coimmunoprecipitated in the presence or absence of KA ( Figure 6C ). Immunoblots showed that the interaction between GluR6/7 and PSD-95 was higher in the hippocampus of Prnp o/o Jnk3 +/+ compared with Prnp +/+ Jnk3 +/+ mice in the presence of KA (1.01 vs. 2.13, respectively; Figure 6C ). Taken together, these data indicate that, in the absence of PrP C , KA treatment increased the binding of GluR6/7-containing KA receptors to PSD-95, which correlates with increased activation of JNK3.
Increased KA-mediated neurotoxicity in Prnp o/o mice was reversed by 6,7-dinitroquinoxaline-2,3-dione and NS-102
To examine the role of GluR6/7 in KA-induced neurotoxicity in Prnp +/+ Jnk3
and Prnp o/o Jnk3 +/+ mice, we injected the AMPA/KA inhibitor 6,7-dinitroquinoxaline-2,3-dione (DNQX) and the GluR6 antagonist NS-102 (Verdoorn et al., 1994) prior to the intraperitoneal injection with KA (Figure 7) . DNQX inhibits AMPA/ KA receptors in vivo (Alford and Grillner, 1990) and inhibits JNK3 activation after excitotoxic insults (Tian et al., 2005) , and NS-102 is a good functional antagonist of GluR6 in vivo in response to excitotoxic insults (Tian et al., 2005 ; C neuroprotection | 3047 Hu et al., 2008; Chen et al., 2009) . First, we counted the seizures and the blinking episodes in treated mice ( Figure 7A ). Pharmacological treatments indicate that preinjection with DNQX and, more effectively, with NS-102 reduced the number of all of the episodes counted in Prnp o/o Jnk3 +/+ mice. Prnp +/+ Jnk3 +/+ mice were almost insensitive to KA, as described earlier ( Figure 7A ). Again, both treatments reduced the number of Fluoro-Jade B-positive cells in the hippocampus ( Figure 7B ) and the presence of p-c-Jun in Prnp o/o Jnk3 +/+ hippocampus in Western blots ( Figure 7C ). In addition, we examined the effect of DNQX and NS-102 on c-Fos expression, which was overexpressed in the hippocampus of Prnp o/o Jnk3 +/+ mice after KA injections (see earlier discussion). Blockage of both AMPA/KA receptors and GluR6 prevented c-Fos overexpression in CA1 ( Figure 7D ) and increased immunostaining of p-ERK1/2 in mossy fibers of Jnk3 +/+ mice in brain sections when examined by different methods (Fluoro-Jade B or TUNEL). Thus c-Jun overexpression cannot be associated with cell death and needs to be phosphorylated by JNK3 to induce cell death. Indeed, JNK3 phosphorylates c-Jun at Ser-63 and Ser-73, and abrogation of c-Jun phosphorylation using alanine mutants for c-Jun at Ser-63 and Ser-73 confers resistance to epileptic seizures and neuronal apoptosis induced by KA (Behrens et al., 1999 
Jnk3
+/+ after KA treatment). This is compatible with the recent proposal that p53 activation after glutamatergic stimulus depends on JNK activity (Choi et al., 2011) .
JNK3-mediated signaling activates the AP-1 complex, which triggers the expression of early response genes such as c-fos or c-jun, as well as the up-regulation of cox-2, which is involved in the inflammatory response after KA treatment (Tu and Bazan, 2003) . In fact, pharmacological inhibition or genetic deletion of cox-2, but not Cox-1, increases susceptibility to KA-induced hippocampal excitotoxicity (Toscano et al., 2008) . In our study, cox-2 was up-regulated after KA treatment in Prnp
, cox-2 expression was largely reduced (up to 60%), indicating a reduction in inflammatory responses in the double-knockout mice. Indeed, a direct relation between JNK activity, c-Jun phosphorylation, and cox-2 up-regulation has been demonstrated in several models (Waetzig et al., 2005) , and the up-regulation of Cox-2 mediated by JNK is necessary and required for neurodegeneration in a mouse model of Parkinson disease (Hunot et al., 2004) .
A putative role of PrP C at the neuronal membrane as modulator of GluR6/7-mediated neurotransmission and JNK3 activity
GluR6 knockout and Jnk3
o/o mice are resistant to KA treatment. In fact, it has been reported that GluR6 binds to PSD-95, and this binding is necessary to trigger GluR6-dependent neurotransmission (Savinainen et al., 2001) due to the formation of a stable trimeric complex GluR6-PSD-95-MLK3 (Li et al., 2010) . In this study we found large colocalization of PrP C with GluR6/7 in the PSD. Moreover, Prnp deletion favors the interaction between PSD-95 and GluR6/7 in the presence of KA. Taken together, our results suggest that absence of PrP C enhances the interaction of the ternary complex PSD-95 and GluR6 and most probably MLK3 at the synapse, thus enabling GluR6-mediated intracellular signaling. This in turn leads to JNK3 activation among that of other kinases.
As mentioned, PrP C has been detected in axon and synaptic contacts, although whether its location is presynaptic or postsynaptic is not fully determined (Fournier et al., 2000; Fournier, 2008) . Here we report that a fraction of PrP C localized to the PSD, where neurotransmitter receptors are located. Recent studies indicate that PrP C is a constitutive basal protector against NMDAmediated toxicity. Deletion of the Prnp gene induces enhanced 2009), which demonstrated that enhanced neurotoxicity to KA in hippocampal slices of Prnp o/o mice has both a KA receptor and a NMDA receptor component. However, the molecular mechanism by which PrP C inhibits NMDA and KA receptors is unclear. PrP C may either influence agonist binding, favor the closed state of the channel, or interfere with the signal transmission, thus forming a negative modulator complex (Steele, 2008) . In any case PrP C expression does not appear to be critical for neuronal glutamate transport (Thais et al., 2006) . Irrespective of the molecular mechanisms responsible for these effects, our data indicate that PrP C (both for KA and NMDA receptors) inhibits glutamatergic neurotransmission and that the absence of PrP C enhances neurotoxic signaling. Furthermore, it is tempting to speculate on a similar protective effect in other brain injuries that share a similar activation mechanism through the receptor complex GluR6/7-PSD-95-MLK3, where signaling is transmitted downstream into the JNK3 pathway. Further studies would be needed to confirm this hypothesis. In this regard, increased levels of PrP C in plasma have been found after acute ischemia in rats and in human stroke patients (Mitsios et al., 2007) . Indeed, Weise et al. (2004) suggested that the extent of the up-regulation of PrP C in ischemic brains depends on the severity of ischemia and may therefore reflect the extent of ischemia-induced neuronal damage. We believe that discerning the functional roles of PrP C at the synapse, as well as its specific interacting partners in normal and pathological conditions at the synapse, would help us to understand neurotoxicity in synapse-associated neurodegenerative diseases and ischemic processes. Figure 8 shows a general scheme depicting the role of the GluR6/7-JNK3 signaling pathway in mediating the neurotoxic effects of KA in mouse hippocampus in the absence of PrP C .
MATERIALS AND METHODS Animals
Prnp knockout mice Zürich I (Prnp o/o ) were purchased from the European Mouse Mutant Archive (EMMA, Monterotondo, Italy). Prnp o/o mice were backcrossed with C57BL6J mice from 10 generations up to obtain 92-95% of C57BL6J microsatellite markers (Charles River background analysis) from the previous 46-48% of the Zürich I mice. Jnk3 knockout mice were generated as described elsewhere (Yang et al., 1997 o/o mice (with 70-75% of C57BL6J microsatellite markers). To avoid putative background-specific differences between mice, all of the experiments were conducted using littermates prolonged NMDA-evoked currents in hippocampal neurons, which increases neuronal excitability and glutamate excitotoxicity (Khosravani et al., 2008) . The same authors described changes in some parameters associated with AMPA/KA-mediated miniature inhibitory postsynaptic currents and γ-aminobutyric acid A-mediated miniature inhibitory postsynaptic currents (Khosravani et al., 2008) . These findings are in concordance with our data (Rangel et al. , 2007, 
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+/+ mice were injected with KA (6 mg/kg body weight) or PBS and analyzed for 4 h. Hippocampi were dissected, and cellular extracts were immunoprecipitated with control and anti-PSD-95 antibodies. Immunoprecipitated samples were developed by Western blot with the anti-GluR6/7 antibody. Densitometry values are standardized with Prnp
+/+ in untreated cultures, and quantification was represented as fold change ± SEM. Notice the increase of GluR6/7 labeling after PSD immunoprecipitation in Prnp
+/+ after KA treatment.
glutamate receptor 6/7 (anti-GluR6/7) antibodies and Fluoro-Jade B were from Millipore (Billerica, MA). SAF61 antibody was from Spi-Bio (Cayman Chemical, Massy, France), and 6H4 antibody was from Prionics (Schlieren, Switzerland). SYBR green was from Roche (Basel, Switzerland).
KA injections
To induce convulsive nonlethal seizures in mice, we developed a progressive KA treatment by administering several consecutive intraperitoneal (i.p.) injections of the glutamate agonist KA dissolved in 0.1 M PBS, pH 7.2 (Rangel et al., 2007) . PBS 0.1 M, pH 7.2 (vehicle), was injected as control. Adult animals (Prnp
; 2-3 mo old) were weighed and i.p. injected with two injections of KA (6 mg/kg body weight) at time 0 and 30 min. Seizure intensity after KA injections was evaluated as described previously during the 4 h after the first KA injection (Peng et al., 1997; Lee et al., 2000) . Tissue samples were analyzed at the indicated times.
derived from heterozygous (Prnp
) parents. Specific primers for Prnp genotyping were designed in our laboratory based on the original P10 and P3 primers described elsewhere (Bueler et al., 1992) . The Jnk3 knockout mice were genotyped as described elsewhere (Kuan et al., 1999) . A total of 45 litters were used in the present study. All experimental procedures were carried out in accordance with the guidelines of the Spanish Ministry of Science and Technology following European standards.
Reagents and antibodies
KA, PI, SP600125, TAT-JIP peptide, DNQX, NS-102, and antitubulin antibody were from Sigma (Poole, United Kingdom). Antip-ERK1/2, total anti-ERK1/2, p-c-Jun (Ser-63), anti-p-JNK, antip-p53 (Ser-15). and total anti-JNK3 antibodies were from Cell Signaling (Beverly, MA). Anti-c-Jun antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-c-Fos was from Calbiochem (Darmstadt, Germany). Postsynaptic density 95 (anti-PSD-95) and Fluoro-Jade B staining of dying neurons in brain sections Coronal brain sections were obtained as described and rinsed for 2 h in 0.1 M Tris, pH 7.4, mounted, and air dried at room temperature overnight. The next day, sections were pretreated for 3 min in absolute ethanol, followed by 1 min in 70% ethanol and 1 min in distilled water. They were then oxidized in a solution of 0.06% KMnO 4 for 15 min. After three rinses of 1 min each in distilled water, the sections were incubated for 30 min in a solution of 0.001% Fluoro-Jade B (Chemicon) containing 0.01% of DAPI (Sigma) in 0.1% acetic acid. The slides were rinsed in deionized water for 3 min each, dried overnight, cleared in xylene, and cover-slipped with Eukitt (Merck, Darmstadt, Germany) and examined using an Olympus (Hamburg, Germany) BX61 epifluorescence microscope.
Neuronal primary cultures and treatments
Primary hippocampal neurons were prepared from the hippocampus of perinatal (embryological day 18 to day of birth) animals. Briefly, hippocampal neurons were grown on dishes coated with poly-d-lysine (30 μg/ml) in Neurobasal medium supplemented with B27, 0.5 mM glutamine, 12.5 mM glutamate, and antibiotics (all purchased from Invitrogen, Carlsbad, CA). At 9 d in vitro (DIV), hippocampal neurons were infected with lentivirus carrying the eGFP construct (Morales et al., 2008) or the siRNA for Prnp. Lentiviral particles were produced by transient transfection of 293FT cells with Lipofectamine 2000 (Invitrogen), using Mission short hairpin RNA prion protein NM_011170 (Sigma), the second-generation packaging construct psPAX2 (Tronolab, Lausanne, Switzerland) , and the envelope plasmid pMD2G (Tronolab). 293FT cells were cultured in DMEM supplemented with 10% fetal calf serum and without antibiotics before transfection. Medium was changed and supplemented with antibiotics after 6 h. Vector supernatants containing viral particles were harvested ∼24 and 48 h later and concentrated by ultracentrifugation (2 h at 26,000 × g at 4°C). After 5 d of infection, cultured neurons were treated with KA (150 μM dissolved in 0.1 M PBS; for 8 h). After treatment, cultures were rinsed twice in KA-free culture medium. The next day, cultures were incubated for 2 h with WST-1 reagent (Roche), and the absorbance (450 nm) was measured in a multiwell plate reader (Merck ELISA System MIOS).
Organotypic slice cultures of hippocampus
Hippocampal slice cultures were prepared from day of birth as described elsewhere (Stoppini et al., 1991 (Stoppini et al., , 1993 del Rio and Soriano, 2010) . Animals were anaesthetized, and brains were removed aseptically from the skull. Horizontal slices (325-350 μm thick) of the hippocampus were obtained using a McIlwain tissue chopper (Mickle Laboratory, Guildford, United Kingdom). Sections were maintained and selected in cold MEM supplemented with glutamine (2 mM; MEM dissecting salt solution) for 45 min. Selected slices were then cultured using the membrane interface method (Stoppini et al., 1991) . Slices were placed on 30-mm-diameter sterile membranes (Millicell-CM, Millipore) and transferred to six-well tissue culture plates (Nunc, Roskilde, Denmark). Cultures were incubated with 1.2 ml of culture medium (50% MEM, 25% horse serum, 25% Hank's buffered salt solution, containing 2 mM glutamine and 0.04% NaHCO 3 , adjusted to pH 7.3). The membrane cultures were maintained in a humidified incubator at 37ºC in a 5% CO 2 atmosphere. The medium was changed every 2 d. All culture reagents were purchased from Invitrogen-Life Technologies (Merelbeke, Belgium).
Neuronal death after treatments in organotypic slice cultures was monitored by PI uptake (Rangel et al., 2007) . After 9 d of culture, hippocampal slice cultures were serum deprived for 3 h, and 150 μM of KA was added. Cultured were exposed to protein JNK
Immunohistochemistry
After KA treatment, mice were perfused with phosphate buffered 4% paraformaldehyde, pH 7.3, postfixed overnight in the same fixative, and cryoprotected in 30% sucrose. Coronal sections (30 μm thick) were obtained in a freezing microtome (Leica, Wetzlar, Germany). Free-floating sections were rinsed in 0.1 M PBS, and endogenous peroxidases were blocked with 3% H 2 O 2 and 10% methanol dissolved in 0.1 M PBS. After extensive rinsing, sections were incubated in 0.1 M PBS containing 0.2% gelatin, 10% normal serum, 0.2% glycine, and 0.2% Triton X-100 for 1 h at room temperature. Sections were then incubated overnight at 4°C with the distinct primary p-ERK1/2 and GFAP antibodies. After washing in 0.1 M PBS containing 0.2% Triton X-100, sections were incubated with Alexa Fluor 488-and/or Alexa Fluor 568-tagged secondary antibodies (1:200 diluted; Molecular Probes, Eugene, OR), washed in 0.1 M, PBS counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 1 μM in 0.1 M PBS; 10 min), and mounted in Fluoromount (Vector Labs, Burlingame, CA). Dying cells in histological sections were measured using the S7100 ApopTag peroxidase in situ apoptosis (TUNEL) detection kit, following the manufacturer's instructions (Chemicon, Temecula, CA). pal fractions, PSD fractions were diluted with RIPA buffer: 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0, up to 500 μl. Samples were processed as described earlier but using RIPA buffer instead of lysis buffer for immunoprecipitation washes. Proteins attached to Sepharose beads were eluted with SDS-PAGE sample buffer, subjected to SDS-PAGE, transferred to PVDF membranes, and probed with the GluR6/7 and PSD-95 antibodies.
RT-qPCR
RT-qPCR was performed on total RNA extracted with the mirVana isolation kit (Ambion, Austin, TX) from the hippocampus of analyzed mice. Purified RNAs were used to generate the corresponding cDNAs, which served as PCR templates for mRNA quantification. The primers used in this study for RT-qPCR validation are given in Supplemental Figure S1 . PCR amplification and detection were performed with the Roche LightCycler 480 detector, using 2x SYBR Green Master Mix (Roche) as reagent, following the manufacturer's instructions. The reaction profile was as follows: denaturation-activation cycle (95°C for 10 min) followed by 40 cycles of denaturationannealing-extension (95°C, 10 min; 72°C, 1 min; 98°C, continuous). mRNA levels were calculated using the LightCycler 480 software. The data were analyzed using the ΔΔCt method, which provides the target gene expression values as fold changes in the problem sample compared with a calibrator sample. Both problem and calibrator samples were normalized by the relative expression of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase [GAPDH] ).
Statistical analysis
All data are presented as mean ± SEM. Pairwise one-way analysis of variance (ANOVA) with Newman-Keuls multiple comparisons test was used for comparison. The operations were performed using Systat Software (Chicago, IL) or Statgraphics (StatPoint Technologies, Warrenton, VA). Statistical significance was set at *p < 0.05, **p < 0.01, and ***p < 0.001. inhibitors (SP600125 20 μM or TAT-JIP 10 μM) for 45 min before KA treatment. After treatment, slices were rinsed twice in KA-free culture medium. The next day, slices were incubated for 2 h with 1 μg/ml of PI dissolved in culture medium. PI-treated slices were fixed for 1 h with 4% buffered paraformaldehyde, pH 7.2. After rinsing, cultures were mounted in Fluoromount and photodocumented in an Olympus confocal microscope. To determine the maximum PI fluorescence for quantification, total fluorescence in the pyramidal layer of the hippocampus was measured in a 500-μm segment of the layer in the CA1-CA3 regions after incubation with 10 mM glutamate for 10 min, using Quantity One Imaging and Analysis software (Bio-Rad Laboratories, Hemel Hempstead, United Kingdom).
PSD purification from mice hippocampus
The PSD fraction was purified from adult mice (10-12 mo old) as indicated (Coba et al., 2009) . Briefly, tissue was weighed, and 1 ml of homogenization buffer (0.32 M sucrose, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] , pH 7.4, 2 mM EDTA, 2.5 mM N-ethylmaleimide, containing protease and phosphatase inhibitors) was added for every 125 mg of tissue. Samples were homogenized in a glass-Teflon Dounce homogenizer (40 strokes) and centrifuged at 800 × g for 10 min at 4°C. The supernatant was centrifuged at 10,000 × g for 15 min at 4°C, and pellet was resuspended in 0.5 ml of Triton buffer: 50 mM HEPES, pH 7.4, 2 mM EDTA, 5 mM EGTA, 1% Triton X-100, 2.5 mM N-ethylmaleimide, containing protease and phosphatase inhibitors) for every 125 mg of tissue. Samples were centrifuged at 50,000 × g for 30 min at 4°C, and the pellet was resuspended in 125 μl of resuspension buffer-50 mM Tris, pH 7.4, 1% SDS (when used for Western blotting) or 50 mM Tris, pH 8.5, 1% deoxycholate (when used for immunoprecipitation experiments)-for every 125 μg of tissue. Samples were incubated for 10 min at room temperature and centrifuged at 50,000 × g for 15 min at 4°C.
Western blotting
Tissue samples from the hippocampus of KA-treated or vehicletreated mice were homogenized (10% wt/vol) in ice-cold lysis buffer-50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (wt/vol) Triton X-100, 0.5% (wt/vol) Nonidet P-40 (IGEPAL; Sigma), glycerol 10%, 1 mM EDTA, 1 mM EGTA, and protease and phosphatase inhibitors-using a motor-driven, glass-Teflon homogenizer in ice and centrifuged at 15,000 × g for 20 min. After protein quantification, tissue extracts were boiled in Laemmli sample buffer at 100ºC for 5 min, followed by 6-10% SDS-PAGE electrophoresis, electrotransferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and processed for immunoblotting and the ECL Plus kit (AmershamPharmacia Biotech, GE Healthcare Bio-Sciences, Piscataway, NJ).
Immunoprecipitation
Cell extracts from total hippocampus or hippocampal PSD fractions were used for immunoprecipitation experiments. For total hippocampus, cell extracts were processed as indicated for Western blot. After protein quantification, 1 mg of hippocampal protein extract was mixed with 10 μl of protein A/G-Sepharose (Sigma) previously equilibrated with lysis buffer-50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl 2 , 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and protease and phosphatase inhibitors-for 2 h (preclearing). Samples were centrifuged, and the supernatant was mixed with the indicated immunoprecipitation antibodies plus 10 μl of protein A/G-Sepharose overnight at 4°C. The immunocomplexes were washed in lysis buffer and once in lysis buffer plus 0.25 M NaCl. For immunoprecipitation from PSD hippocam-
